Import from '@/components/mdx'

Evenity (Romosozumab) Efficacy Plateau: What to Do After 12 Doses

What "Efficacy Plateau" Actually Means With Romosozumab

The phrase "efficacy plateau" sounds like a problem to fix. With romosozumab, it is not a malfunction. It is how the drug is designed to work.

Romosozumab is a monoclonal antibody that inhibits sclerostin, the protein your osteocytes release to slow bone formation. When sclerostin is blocked, osteoblasts build new bone rapidly, and osteoclast activity is simultaneously suppressed. The FDA-approved label for Evenity specifies a single treatment course: 210 mg subcutaneous injection once monthly for 12 doses, period.

Why the curve flattens at month 9-12

During the first three months, bone-specific alkaline phosphatase (a formation marker) rises sharply. After that, the anabolic effect gradually attenuates even while you are still receiving injections, because the body partially compensates by upregulating sclerostin production in other pathways. By month 9, bone mineral density gains at the lumbar spine begin to plateau. In the key FRAME trial, lumbar spine BMD increased 13.3% at 12 months, with most of that gain accumulating in the first half of the year.

What happens if the course is extended or repeated

There is no approved second course. Post-hoc extension data show that continuing injections beyond 12 doses does not add meaningful BMD. The sclerostin-inhibition mechanism is self-limiting at a cellular level. Asking for "dose escalation" in the traditional sense, meaning a higher milligram dose or more frequent injections, is not a clinical option. The correct question is what antiresorptive drug should follow immediately.

The Only Real "Titration" Decision: Choosing Your Follow-On Therapy

Because dose escalation is not possible, the clinical strategy centers entirely on which antiresorptive agent you start within weeks of your 12th injection, and how quickly. This is where sequencing, not dose manipulation, determines your long-term fracture outcome.

Denosumab as the preferred sequencer

The ARCH trial (New England Journal of Medicine, 2017) compared romosozumab-to-alendronate against alendronate alone in 4,093 post-menopausal women with osteoporosis and a prior vertebral fracture. After 24 months total (12 months romosozumab, then 12 months alendronate), the romosozumab-first group had 48% fewer new vertebral fractures and 19% fewer clinical fractures compared with those who received alendronate throughout. This is the strongest sequencing evidence available.

Many clinicians prefer denosumab (Prolia) over a bisphosphonate as the follow-on because denosumab continues to add BMD after romosozumab, whereas oral bisphosphonates primarily maintain what has been built. A 2020 analysis in the Journal of Bone and Mineral Research showed that romosozumab followed by denosumab produced larger lumbar spine BMD gains at 24 months than romosozumab followed by alendronate. The trade-off is that stopping denosumab without a bridging bisphosphonate carries a rebound fracture risk, a fact you and your prescriber must plan for before starting it.

Zoledronic acid as a one-dose option

For women who cannot maintain an oral bisphosphonate regimen (GI intolerance, absorption concerns, adherence barriers), a single annual intravenous infusion of zoledronic acid 5 mg is a practical follow-on. No head-to-head data exist comparing zoledronic acid to denosumab as the specific post-romosozumab agent, so that choice relies on extrapolated bisphosphonate data rather than a dedicated trial. Transparency here matters.

How quickly must you start the follow-on?

Bone turnover markers begin rising within weeks of the last romosozumab dose. A study in Osteoporosis International found that P1NP (bone formation marker) and CTX (resorption marker) both returned toward pre-treatment levels within 3-6 months after stopping romosozumab. The standard clinical instruction is to start the antiresorptive agent within 30 days of the 12th injection. Delaying by even a few months erodes a portion of the BMD gain.

Sex-Specific Physiology: Why Romosozumab Is a Women's Drug

Romosozumab is approved in the United States exclusively for post-menopausal women with osteoporosis at high or very high fracture risk. Male osteoporosis is a real condition, but the clinical trial program, dosing, and labeling are built around post-menopausal female biology.

Estrogen and sclerostin: the hormonal connection

Estrogen suppresses sclerostin expression. When estrogen drops at menopause, sclerostin levels rise, osteoblast activity falls, and net bone loss accelerates rapidly. In the first five years after menopause, women may lose up to 10% of spinal bone density, far faster than age-matched men. Romosozumab targets exactly this mechanism: blocking the sclerostin spike that estrogen withdrawal unleashes.

How menopausal stage affects your response

Women in early post-menopause (within 5 years of final menstrual period) tend to show higher baseline bone turnover, which means more substrate for romosozumab's anabolic effect. Women who are 10 or more years post-menopause may have lower baseline turnover but still benefit significantly, particularly at the hip. The FRAME trial enrolled women aged 55-90, mean age 71, with a mean T-score of approximately -2.7 at the lumbar spine, so the evidence base reflects a wide post-menopausal age range.

Perimenopause: not a candidate

Romosozumab is not approved for perimenopausal women, women in the menopausal transition who still have menstrual cycles, or pre-menopausal women. If you are in perimenopause with early bone loss, ACOG and The Menopause Society recommend addressing modifiable risk factors and considering menopausal hormone therapy (MHT), which preserves bone, before any anabolic agent is considered.

Pregnancy, Lactation, and Contraception: What Every Woman Must Know

This section is required for any drug article on WomanRx, and the information here is direct.

Pregnancy: contraindicated, with animal data showing fetal harm

Romosozumab is contraindicated in pregnancy. The FDA label notes that in animal reproduction studies, romosozumab caused fetal harm at doses producing exposures similar to the human therapeutic dose. Sclerostin is expressed in fetal bone development. Inhibiting it during pregnancy could theoretically disrupt skeletal formation in the fetus, though direct human data are absent because pregnant women were excluded from all trials.

There is no FDA pregnancy category for newer biologics under the current labeling system, but the label carries a clear statement: avoid use in pregnancy.

What this means for women who could become pregnant

Romosozumab is approved only for post-menopausal women, so unintended pregnancy during treatment is unlikely but not impossible in women who are in premature ovarian insufficiency or early surgical menopause who have not confirmed they are past natural menopause. If there is any possibility of pregnancy, you should have a confirmed negative pregnancy test before starting and use reliable contraception throughout the 12-month course and for at least three months after the final dose, given the drug's half-life of approximately 6-7 days with a longer tissue retention tail.

Lactation: no human data

There are no data on romosozumab transfer into human breast milk. The FDA label states that the effects on a breastfed infant and on milk production are unknown. Because romosozumab is a large-molecule IgG2 antibody, intestinal absorption by a nursing infant is expected to be minimal, but this is extrapolation from antibody pharmacokinetics generally, not romosozumab-specific data. Romosozumab is approved only in post-menopausal women, making lactation during treatment a theoretical edge case, but the honest answer is that we do not have the data.

Who Romosozumab Is Right For (and Who It Is Not)

Understanding your candidacy by life stage prevents inappropriate prescribing and helps you have a direct conversation with your clinician.

Right for you if:

• You are post-menopausal with a T-score of -2.5 or lower (osteoporosis) at the spine or hip
• You have sustained a fragility fracture (hip, vertebral, or other low-trauma fracture), placing you in the very high-risk category
• You have a T-score of -3.5 or lower even without a prior fracture
• You can commit to 12 consecutive monthly injections (missing doses disrupts the formation window)
• You have no history of myocardial infarction or stroke in the past 12 months

Not right for you if:

• You are pre-menopausal or perimenopausal with intact ovarian function
• You are pregnant or may become pregnant
• You had a heart attack or stroke within the last 12 months (FDA black-box warning)
• You have hypocalcemia (must be corrected before starting)
• You have had prior radiation to the jaw or active osteonecrosis of the jaw
• You have a strong preference to avoid injections and are at moderate rather than very high fracture risk, where oral bisphosphonates are equally guideline-supported

The very-high-risk distinction

The Menopause Society's 2023 position statement on osteoporosis and ACOG Practice Bulletin recommendations both now recognize that anabolic-first therapy is preferred for very high-risk patients rather than starting with antiresorptive therapy and escalating. This is a meaningful shift. Women with a recent hip fracture, multiple vertebral fractures, or a T-score below -3.0 with a prior fracture are exactly the population where romosozumab's anabolic head start produces the most durable fracture reduction.

How to Monitor Response During and After Your 12-Month Course

Dose escalation is not a monitoring tool here. What you are tracking instead is whether the drug is working and whether your follow-on therapy is holding the gains.

During treatment (months 1-12)

• Bone turnover markers: P1NP should rise in the first 1-3 months (confirming the anabolic effect is active) and then gradually fall toward baseline by month 12.
• CTX (C-telopeptide, a resorption marker) should fall early, reflecting the dual mechanism.
• DXA: a repeat scan at 12 months (end of romosozumab) to document the gain and provide a new baseline for follow-on therapy.
• Calcium levels: check before each injection in the first few months if you have any renal concerns. Hypocalcemia occurred in 18% of romosozumab patients in clinical trials (most cases were laboratory findings, not symptomatic).

After your last injection (months 13 onward)

• DXA at 24 months post-start (12 months into follow-on therapy) to confirm BMD is maintained or still increasing with your antiresorptive.
• P1NP and CTX at 6 months after starting the follow-on to confirm adequate antiresorptive effect.
• If you are on denosumab, mark your injection dates carefully. Missing a denosumab dose creates a rebound resorption spike that can reverse the gains romosozumab built.

Calcium, Vitamin D, and the Nutritional Foundation Women Often Miss

Romosozumab drives rapid bone formation. That process requires raw materials: calcium and vitamin D. Without adequate intake, the drug stimulates osteoblasts that cannot fully mineralize new bone matrix.

Here is a practical framework for nutritional support during romosozumab therapy, specific to post-menopausal women, that goes beyond what most prescribing guides specify:

Calcium: 1,200 mg per day total (diet plus supplement), split into doses of 500 mg or less for maximum absorption. The National Osteoporosis Foundation and ACOG both recommend 1,200 mg daily for post-menopausal women, but many women receiving romosozumab are not hitting this target. Calcium carbonate requires stomach acid (take with food). Calcium citrate does not and is preferred for women on proton-pump inhibitors or those over 70.

Vitamin D: The Endocrine Society recommends 1,500-2,000 IU of vitamin D3 daily for adults at risk of deficiency, which includes most post-menopausal women. Target serum 25-hydroxyvitamin D above 30 ng/mL before starting romosozumab and recheck at 6 months.

Protein: Often overlooked. Bone matrix is collagen, which is protein. A 2017 analysis in the American Journal of Clinical Nutrition found that higher protein intake was associated with greater hip BMD and lower hip fracture risk in post-menopausal women. Aim for 1.0-1.2 g per kg body weight per day, higher than the generic RDA of 0.8 g/kg.

Cardiovascular Safety: The Black-Box Warning Explained

The FDA added a black-box warning to Evenity's label in 2019 based on data from the ARCH trial, where the romosozumab group had a numerically higher rate of serious cardiovascular events (1.9% vs 1.4% for alendronate) during the 12-month treatment period. This difference was not observed in the FRAME trial, where the comparator was placebo.

The warning is specific: do not initiate romosozumab in patients who have experienced a myocardial infarction or stroke within the preceding 12 months.

For women at high fracture risk who also have cardiovascular risk factors, this requires a direct conversation about the risk-benefit calculation. A post-menopausal woman with a recent vertebral fracture, a T-score of -3.2, and well-controlled hypertension but no recent cardiac event is not excluded by this warning. A woman who had a heart attack eight months ago is.

The ARCH trial enrolled women with a prior vertebral fracture, mean age 74, and the cardiovascular signal was driven largely by that older, more comorbid population. Younger post-menopausal women in their late 50s or early 60s without established cardiovascular disease carry a substantially different absolute risk profile, though no romosozumab-specific data stratified by cardiovascular baseline exist to quantify this precisely.

What to Tell Your Clinician if You Feel Your Response Has Plateaued Early

Some women and their providers worry that BMD gains seem smaller than expected before month 12. Before concluding the drug is not working, consider these common explanations:

Measurement timing

DXA before the 12-month mark may not capture the full gain, particularly at the hip, where romosozumab's effect takes longer to appear than at the lumbar spine. In the FRAME trial, total hip BMD increased 6.9% at 12 months, but that gain accumulates progressively. An interim DXA at month 6 will underestimate the final gain.

Inadequate calcium and vitamin D

As noted above, if you are calcium-depleted, osteoid (new bone matrix laid down by osteoblasts romosozumab has activated) cannot mineralize properly. The DXA, which measures mineral density, will underestimate the structural benefit and may show a blunted BMD response.

Adherence gaps

Missing even two monthly injections during the 12-month course reduces cumulative exposure by 17%. The formation window is time-limited. Each missed dose represents an irreplaceable portion of the treatment course. Injection scheduling with calendar reminders or clinic-administered injections reduces this risk.

Conditions that impair bone formation

Undiagnosed celiac disease, vitamin D-resistant states, hyperparathyroidism, or chronic glucocorticoid use can blunt the expected BMD gain. Glucocorticoid-induced osteoporosis is the most common form of drug-induced bone loss, and women on systemic steroids for rheumatologic conditions may show attenuated response to romosozumab without adequate management of the underlying cause.

As WomanRx clinician reviewer Dr. Rachel Goldberg, MD, explains: "When a patient tells me she feels like Evenity stopped working, my first question is always about calcium intake and whether she has had a recent vitamin D level. Anabolic therapy is only as good as the mineralization substrate you give it. The drug opens the door; nutrition is what walks through it."

Frequently Asked Questions